Kiadis Pharma proposes former Cipla CEO Subhanu Saxena as new Supervisory Board member

Amsterdam-Duivendrecht, The Netherlands, January 16, 2018 – Kiadis Pharma N.V. (“Kiadis Pharma” or the “Company”) (Euronext Amsterdam and Brussels: KDS), a clinical stage biopharmaceutical company developing innovative T-cell therapy products to make bone marrow transplantations safer and more effective for patients, today announces that at its next General Meeting of Shareholders, the Kiadis Pharma Supervisory Board will nominate Subhanu Saxena to be appointed as a new member of the Supervisory Board.
Subhanu Saxena is currently a Regional Director with The Bill & Melinda Gates Foundation as well as partner New Rhein Healthcare and Senior Advisor to Bain Capital. He was, until recently, the Managing Director and Global Chief Executive Officer of Cipla, a publicly listed, leading Indian pharmaceutical and biotech company with global operations and around 25,000 employees. During Mr. Saxena’s leadership Cipla was transformed into a more international and agile company. Prior to joining Cipla, Mr. Saxena was Head of Global Product Strategy and Commercialization and member of the Executive Committee at Novartis. Before that, Mr. Saxena was CEO of Novartis UK and held various leadership roles in business development. Prior to joining the pharma industry Mr. Saxena worked with leading global companies including Citicorp, the Boston Consulting Group and PepsiCo across markets in Europe, North America, Africa and Asia. Mr. Saxena holds a Graduate degree in Engineering from Oxford University and an MBA from INSEAD, France.

Arthur Lahr, CEO of Kiadis Pharma, commented: “I am delighted Subhanu has decided to join our Supervisory Board. As we continue to professionalize our company and prepare for the potential European commercial launch of ATIR101™ in H2 2019, Subhanu’s vast leadership experience in building and transforming a wide variety of organizations will be of immense value for Kiadis Pharma and help us tremendously to make ATIR101™ widely available to patients.’’

Subhanu Saxena added: “I am very pleased to join the Kiadis Pharma Supervisory Board and am impressed by the Company’s investigational product and technology platform, which I am convinced can serve patients with a safer and more effective bone marrow transplantation. I look forward to support the further maturing of Kiadis Pharma.’’

Mark Wegter, Chairman of the Supervisory Board of Kiadis Pharma, commented: “We are very happy to welcome Subhanu to our Supervisory Board. His wealth of global strategic and commercial experience will be invaluable to Kiadis Pharma in the next stages of its growth and continued transformation into a successful commercial stage company.

Leave a comment

Your email address will not be published. Required fields are marked *